Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Gerolf Kraus is active.

Publication


Featured researches published by Gerolf Kraus.


European Journal of Pharmaceutics and Biopharmaceutics | 1998

Optimization of an effervescent tablet formulation using a central composite design optimization of an effervescent tablet formulation containing spray dried l-leucine and polyethylene glycol 6000 as lubricants using a central composite design

Bärbel Rotthäuser; Gerolf Kraus; Peter C. Schmidt

A rotatable central composite design is used to evaluate the effects of lubricants and compression force on the physical characteristics of effervescent tablets. Effervescent tablets lubricated with a combination of spray dried L-leucine and polyethylene glycol 6000 are prepared by direct compression and examined. Residual force, crushing strength and disintegration time are considered as response variables and related to the L-leucine and polyethylene glycol concentrations and to the compression force. The calculated models are used to assess the influence of the production factors on tablet properties. As increasing amounts of L-leucine, showing good lubricating properties, reduce the crushing strength and prolong tablet disintegration, the L-leucine concentration is kept at a low level. An optimum tablet formulation contains 2% L-leucine and 3% polyethylene glycol 6000. The tablets have a tensile strength of 0.47 MPa and disintegrate in less than 2 min. Predicted and experimental results are in agreement within a 95% CI.


Transplant Immunology | 1999

A novel immunosuppressant, FTY720, induces peripheral lymphodepletion of both T- and B cells and immunosuppression in baboons

Valerie Quesniaux; Lynn Fullard; Hiram Arendse; Glenda Davison; Noel Markgraaff; Roland Auer; Francis Ehrhart; Gerolf Kraus; Henk-Jan Schuurman

OBJECTIVE FTY720, a new immunosuppressant active in transplantation models, modulates lymphocyte re-circulation, leading to peripheral lymphopenia and increased lymphocytes in lymph nodes and Peyers patches. Here, we investigated the susceptibility of baboons to FTY720 as an introductory study to transplantation protocols. METHODS FTY720 was administered orally to Chacma baboons at 0.3 or 0.1 mg/kg/day for 3 days or at 0.03 mg/kg/day for 10 days. Haematological parameters, lymphocyte phenotype (CD3, CD4, CD8, CD20), cell apoptosis, ex vivo blood cell proliferation in response to mitogens and drug blood levels were monitored during treatment and up to 4 weeks thereafter. MAIN FINDINGS FTY720 administered p.o. in baboons at 0.3 mg/kg/day caused a marked decrease in circulating lymphocytes within 4 h of treatment, reaching 60-80% decrease within 24-48 h. The effect of FTY720 was seen both on T- and B cells, although it was slightly more rapid/pronounced on T cells. CD4+ cells were slightly more affected than CD8+ cells. The response onset was faster and the duration longer at higher dose, but the maximal peripheral lymphodepletion achieved was similar within the dose range 0.03-0.3 mg/kg tested. Ex vivo mitogen-induced lymphoproliferation was drastically decreased after FTY720 treatment, corresponding to the reduced blood lymphocyte counts. The blood drug levels measured after FTY720 administration correlated well with the dose applied but there was a poor correlation between FTY720 blood levels and the extent of peripheral lymphodepletion, suggestive of a high tissue distribution of the drug. When compared with cynomolgus monkeys treated in the same way, baboons had a lower initial exposure and a slightly lower response 24 h after one or two doses of FTY720 0.03-0.3 mg/kg. However, the stabilized drug blood levels and peripheral lymphodepletion achieved after 7 days of FTY720 0.03 mg/kg/day were similar in both nonhuman primate species. CONCLUSIONS FTY720 was well tolerated and was effective in terms of peripheral T- and B lymphodepletion in baboons, indicating that it could be used in protocols of allo- and xenotransplantation. The pharmacokinetic and pharmacodynamic profiles of FTY720 in baboons suggest the use of high induction doses to optimize immediate response followed by a reduced dose regimen for drug maintenance.


Transplant Immunology | 2000

The novel immunosuppressant FTY720 induces peripheral lymphodepletion of both T- and B-cells in cynomolgus monkeys when given alone, with Cyclosporine Neoral® or with RAD

Valerie Quesniaux; Klaus Menninger; Adrien Kunkler; Corinne Vedrine; Mario Bernhard; Rene Hedinger; Gerolf Kraus; Henk-Jan Schuurman

OBJECTIVE FTY720 is a new immunosuppressant active in transplantation models, which modulates lymphocyte recirculation, leading to transient peripheral lymphopenia and increased lymphocytes in lymph nodes and Peyers patches. Here, we investigated the susceptibility of cynomolgus monkeys to FTY720 given orally either alone or in combination with two other immunosuppressants, Cyclosporin Neoral or RAD, as an introductory study to transplantation protocols. METHODS Each of the three phases of the study comprised a 3-week treatment period with FTY720 administered daily orally at 0.3, 0.1 or 0.03 mg/kg/day, respectively, followed by a 3-week recovery. FTY720 was given as single compound during the first week and in combination with Neoral at 20 mg/kg/day p.o. or RAD at 0.5 mg/kg/day p.o. during the subsequent 2 weeks. MAIN FINDINGS These treatment regimen were well tolerated, except for some body weight loss at high FTY720 dose (0.3 mg/kg/day). FTY720 treatment resulted in a rapid decrease of white blood cell counts which reached a plateau after 3 days. A decrease in both T- and B-lymphocyte counts by up to 80-90% was seen with FTY720 doses of 0.1 and 0.3 mg/kg/day. FTY720 blood levels, both trough levels and AUC(0-24 h), showed a linear relationship with FTY720 dose. The reduction in lymphocyte counts was not directly proportional to FTY720 blood levels. The exposure to FTY720 significantly increased upon coadministration of Neoral. This pharmacokinetic interaction was not observed for coadministration of RAD. However, the peripheral lymphodepletion was slightly increased after coadministration of RAD but not of Neoral. This may be related to the intrinsic effects of RAD on hematopoietic cells. CONCLUSIONS FTY720 given orally was effective in terms of peripheral T- and B-lymphodepletion and was well tolerated in cynomolgus monkeys even in combination with Cyclosporine Neoral or RAD, indicating that such combination protocols could be used in allo- and xenotransplantation in this species. However, the data indicate a potentiation of FTY720 exposure by CsA coadministration and additional lymphodepletion by coadministration of FTY720 and RAD which should be carefully monitored.


Proceedings of the International Solid-State Sensors and Actuators Conference - TRANSDUCERS '95 | 1995

Performance And Limitations Of Reflectometric Fibre Optical Sensors For Voc Sensing Applications

Jens Seemann; Gerolf Kraus; Giinter Gauglitz

Interferometric optical sensors are known for the exact determination of path lengths. Equipped with appropriate sensitive polymer coatings, this effect can be used to monitor changes in VOC concentration in vapour phase and water. The performance and limitations of a fibre optical RUS-transducer are reported here with respect to optical components, temperature variation and properties of the polymer coating.


Journal of The American Society of Nephrology | 2002

First Human Trial of FTY720, a Novel Immunomodulator, in Stable Renal Transplant Patients

Klemens Budde; Robert L. Schmouder; R. Brunkhorst; Björn Nashan; Peter W. Lücker; Thomas Mayer; Somesh Choudhury; Andrej Skerjanec; Gerolf Kraus; Hans H. Neumayer


Archive | 1997

Optical chemical/biochemical sensor

Gert Ludwig Duveneck; Jürg Dübendorfer; Rino E. Kunz; Gerolf Kraus


Langmuir | 1999

Highly Oriented, Self-Assembled Alkanephosphate Monolayers on Tantalum(V) Oxide Surfaces

Dorothee Brovelli; Georg Hähner; Laurence Ruiz; Rolf Hofer; Gerolf Kraus; Adrian Waldner; Johanna Schlösser; Peter Oroszlan; Markus Ehrat; Nicholas D. Spencer


British Journal of Clinical Pharmacology | 2004

Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects.

John M. Kovarik; Robert Schmouder; Denise Barilla; Yibin Wang; Gerolf Kraus


Archive | 1997

Measuring device and its use

Gerolf Kraus; Michael Pawlak; Gert Ludwig Duveneck; Peter Oroszlan; Andreas Helg; Alfredo Emilio Bruno-Raimondi


Archive | 2000

Measuring device and the use thereof

Gerolf Kraus; Michael Pawlak; Gert Ludwig Duveneck; Peter Oroszlan; Andreas Helg; Alfredo Emilio Bruno-Raimondi

Collaboration


Dive into the Gerolf Kraus's collaboration.

Researchain Logo
Decentralizing Knowledge